Mirae Asset Global Investments Co. Ltd. Purchases New Stake in Amgen Inc. $AMGN

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 811,229 shares of the medical research company’s stock, valued at approximately $341,941,000. Amgen makes up approximately 0.6% of Mirae Asset Global Investments Co. Ltd.’s holdings, making the stock its 25th largest holding. Mirae Asset Global Investments Co. Ltd. owned about 0.15% of Amgen at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Aviance Capital Partners LLC lifted its stake in shares of Amgen by 0.7% during the third quarter. Aviance Capital Partners LLC now owns 37,246 shares of the medical research company’s stock worth $15,699,000 after purchasing an additional 248 shares in the last quarter. Northern Financial Advisors Inc grew its stake in shares of Amgen by 1.0% in the third quarter. Northern Financial Advisors Inc now owns 3,886 shares of the medical research company’s stock valued at $1,638,000 after buying an additional 39 shares in the last quarter. Stevens Capital Partners acquired a new stake in shares of Amgen in the third quarter valued at about $344,000. ProShare Advisors LLC grew its stake in shares of Amgen by 2.3% in the third quarter. ProShare Advisors LLC now owns 713,097 shares of the medical research company’s stock valued at $300,578,000 after buying an additional 16,067 shares in the last quarter. Finally, Vise Technologies Inc. purchased a new stake in shares of Amgen during the 3rd quarter valued at about $16,189,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AMGN shares. TD Cowen boosted their price target on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein lifted their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Oppenheimer reissued an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. Mizuho boosted their target price on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Finally, UBS Group upped their target price on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a research note on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $389.71.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. Corporate insiders own 0.85% of the company’s stock.

Amgen Trading Up 1.1%

Shares of AMGN opened at $466.01 on Friday. The company has a market capitalization of $251.94 billion, a P/E ratio of 28.96, a P/E/G ratio of 3.41 and a beta of 0.41. Amgen Inc. has a one year low of $288.00 and a one year high of $475.65. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a 50-day moving average price of $419.96 and a 200 day moving average price of $374.79.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the business earned $6.02 EPS. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.